Wed, 30 Sep 2026 · LIVE
Updated Jul 22, 2026 · 17:45
Business India News Updated Jul 22, 2026

Sensex Tumbles Over 400 Points, Nifty Below 24,150 on Pharma Selloff

Indian benchmark indices opened lower on Wednesday, with the Sensex falling over 400 points and the Nifty slipping below 24,150, driven by surging crude oil prices and pressure on pharmaceutical stocks. US President Donald Trump announced plans to impose tariffs of up to 200% on generic drug imports from 2028, causing Nifty Pharma to drop 1.64% and key stocks like Sun Pharma, Aurobindo Pharma, and Lupin to decline. Brent crude traded near $92 per barrel amid escalating US-Iran tensions, adding to investor caution. Analysts noted that the market remains range-bound with support at 24,000 and resistance at 24,200, as geopolitical risks and Q1 earnings season dictate near-term direction.

Sensex falls over 400 points, Nifty slips below 24,150 amid crude surge, pharma stocks under pressure following Trump's tariff announcement

Mumbai, July 22

Indian benchmark indices opened lower on Wednesday as surging crude oil prices amid escalating tensions between the US and Iran weighed on investor sentiment, while Indian pharmaceutical stocks came under pressure after US President Donald Trump announced plans to impose tariffs of up to 200 per cent on generic drug imports from 2028.

Trump announced generic drugs imported into the US will continue to attract zero per cent tariffs for two years from August 1, 2026, after which the tariff will rise to 100 per cent for one year and 200 per cent thereafter. The announcement put pressure on Indian pharma stocks, with several companies trading in the red during early trade.

Sensex opened with a gap-down at 77,384.95 as against previous close of 77,470.11 while Nifty opened at 24,150.45 as against previous close of 24,187.70. The indice was trading at around 77,065.53, down 404.58 points or 0.52 per cent while Nifty was trading at around 24,093.20, down 94.50 points or 0.39 per cent, at the time of reporting.

Sectorally, most indices traded in the red with Nifty Pharma emerging as top loser, shedding 1.64 per cent in the early morning trade, while metal, auto, and consumer durables traded in the green during the early morning trade.

On BSE, only Maruti, Titan, Eternal, Hindustan Unilever, M&M and Trent were the major gainers. Indi Go, Axis Bank, Sun Pharma, Infosys, Tech Mahindra, ITC, Reliance, BEL, ITC, Tata Steel, Adani Ports, Power Grid among others were the major losers.

Companies with higher US revenue were trading in the red during the early morning trade. Sun Pharma was trading in the red at around Rs 1936.95, down 25.20 points or 1.28 per cent.

Aurobindo Pharma too was trading in the red at Rs 1531, down 49.45 points or 3.13 per cent, Cipla was trading at around Rs 1403, down 29.55 points or 2.06 per cent and Lupin was trading at around Rs 2437.70, down 76.70 points or 3.05 per cent, at the time of reporting.

In the commodity market, Brent crude was trading at around USD 92.04/barrel while crude oil was trading at around USD 85.26 per barrel, at the time of reporting.

Banking and market analyst Ajay Bagga noted, "Indian markets are showing a divergence with the advance/decline ratio positive but a selloff in key private banks leading to negative market performance over the last two days. As of this morning, the Indian markets are expected to open slighltly lower . Oil price impact will start showing up in the currency, the balance of payments and the projected fiscal deficit number."

Market analyst Vipin Dixena noted, "In my view, the market is likely to remain range-bound in the near term as persistent geopolitical tensions in West Asia, elevated Brent crude prices near $90 per barrel, a weak rupee, continued FII selling, and mixed global cues keep investors cautious. That said, the ongoing Q1 earnings season is expected to shift the focus towards stock-specific opportunities, with corporate earnings likely to play a decisive role in driving market direction alongside developments in West Asia and the movement in crude oil prices."

"The opening trade indicates that bears remain in control, with broader market sentiment turning defensive. And Nifty is trading below EMA 50 signalling short-term weakness. Additionally The RSI has slipped to around 34, reflecting strengthening bearish momentum, although it is approaching the oversold zone," he said.

"On the downside, 24,000 is the immediate support to watch. A sustained break below this level could extend the decline towards the 23,900-23,850 zone. On the upside, 24,200 now becomes the immediate resistance, and only a decisive move above this range may help the index regain positive momentum," he noted.

— ANI

Reader Comments

Priya S

Our pharma companies need to diversify beyond US markets. Africa, Southeast Asia, Europe - there's huge potential. Relying on one customer is risky business. This tariff talk is a wake-up call for India Inc.

Vikram M

Meanwhile, crude at $92 and our rupee sliding. The government talks about 'Amrit Kaal' but ground reality is different. Inflation, weak currency, FII selling - retail investors are getting hammered. Need some genuine reforms, not just slogans.

Rohit P

Nifty 24,000 support - ab yeh bhi tuta toh fir 23,500 tak jayega. I've been booking profits in pharma since last quarter. Trump's tariff threat or not, valuations were stretched. Market correction is healthy, buy the dip if you have patience. 📉📈

Michael C

As someone who tracks global pharma supply chains, I'd say this is typical Trump election-year rhetoric. The US simply can't afford to tariff 40% of its generic drugs - it would spike healthcare costs and inflation. Indian Pharma will be fine, but the volatility is painful for short-term traders.

Sneha F

Thoda patience rakho guys. Every year there's some US threat, some Middle East tension. Our economy is resilient. Focus on SIPs, don't check portfolio daily. Woh 200% tariff toh 2028 se hai - tab tak kya pata kya ho. 😊

We welcome thoughtful discussions from our readers. Please keep comments respectful and on-topic.

Reader Voices

Leave a comment

Be kind. Add to the conversation. 0/50
Thank you — your comment has been submitted.
JS blocked